Clinical trial • Phase III • Oncology
Clinical trial in Non-Hodgkin lymphoma | B-cell non-Hodgkin lymphoma
Phase III trial for Non-Hodgkin lymphoma | B-cell non-Hodgkin lymphoma. 78 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Non-Hodgkin lymphoma | B-cell non-Hodgkin lymphoma
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 03-07-2024
- First CTIS Authorization Date
- 24-07-2024
Trial design
Phase III trial across 13 sites in Spain, Italy.
- Target Sample Size
- 78
Recruitment
- Planned Sample Size
- 78
- Recruitment Window Months
- 48
Geography
- Total Number Of Sites
- 13
- Total Number Of Participants
- 52
Spain
- Earliest CTIS Part Ii Submission Date
- 18-07-2024
- Latest Decision Or Authorization Date
- 12-11-2025
- Processing Time Days
- 482
- Number Of Sites
- 7
- Number Of Participants
- 32
Sites
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Oncology
- Contact Person Name
- Pau Abrisqueta
- Contact Person Email
- pabrisqueta@vhebron.net
- Site Name
- Clinica Universidad De Navarra
- Department Name
- Oncology
- Contact Person Name
- Carlos Grande García
- Contact Person Email
- cgrandeg@unav.es
- Site Name
- Institut Catala D'oncologia
- Department Name
- Oncology
- Contact Person Name
- Eva María González-Barca
- Contact Person Email
- e.gonzalez@iconcologia.net
- Site Name
- Hospital Universitario Y Politecnico La Fe
- Department Name
- Oncology
- Contact Person Name
- Isidro Jarque Ramos
- Contact Person Email
- jarque_isi@gva.es
- Site Name
- Hospital Universitario De Salamanca
- Department Name
- Oncology
- Contact Person Name
- Alejandro Martín
- Contact Person Email
- amartingarcia@saludcastillayleon.es
- Site Name
- Hospital General Universitario Gregorio Maranon
- Department Name
- Oncology
- Contact Person Name
- Mariana Bastos Oreiro
- Contact Person Email
- marianabeatriz.bastos@salud.madrid.org
- Site Name
- Hospital Universitari Vall D Hebron (duplicate entry if present)
- Department Name
- Oncology
- Contact Person Name
- Pau Abrisqueta
- Contact Person Email
- pabrisqueta@vhebron.net
Italy
- Earliest CTIS Part Ii Submission Date
- 18-07-2024
- Latest Decision Or Authorization Date
- 10-11-2025
- Processing Time Days
- 480
- Number Of Sites
- 6
- Number Of Participants
- 20
Sites
- Site Name
- Ospedale San Raffaele S.r.l.
- Department Name
- Lymphoma Unit - Department of Onco-Hematology
- Contact Person Name
- Andres Jose Maria Ferreri
- Contact Person Email
- ferrari.andres@hsr.it
- Site Name
- Azienda Ospedaliero Universitaria Pisana
- Department Name
- Hematology Department
- Contact Person Name
- Sara Galimberti
- Contact Person Email
- sara.galimberti@unipi.it
- Site Name
- Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
- Department Name
- Hematology Unit
- Contact Person Name
- Pierluigi Zinzani
- Contact Person Email
- pierluigi.zinzani@unibo.it
- Site Name
- Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
- Department Name
- Hematology Department
- Contact Person Name
- Alessandra Tucci
- Contact Person Email
- alessandra.tucci@asst-spedalicivili.it
- Site Name
- Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
- Department Name
- Hematology Department
- Contact Person Name
- Gerardo Musuraca
- Contact Person Email
- gerardo.musuraca@irst.emr.it
- Site Name
- Ospedale San Raffaele S.r.l. (duplicate entry if present)
- Department Name
- Lymphoma Unit - Department of Onco-Hematology
- Contact Person Name
- Andres Jose Maria Ferreri
- Contact Person Email
- ferrari.andres@hsr.it
Sponsor
Primary sponsor
- Full Name
- F. Hoffmann-La Roche AG
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Switzerland
Investigational products
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)